James L. Januzzi, MD, is the Hutter Family Professor of Medicine at Harvard Medical School, a staff cardiologist at Massachusetts General Hospital, and Senior Cardiometabolic Faculty at Baim Institute for Clinical Research. After completing his undergraduate studies at Holy Cross College in 1988, Dr. Januzzi graduated at the top-ranked student at New York Medical College, and subsequently performed a residency in Internal Medicine at Brigham and Women’s Hospital and fellowship in Cardiology and Cardiac Ultrasound at the Massachusetts General Hospital. He joined the Cardiology Division at MGH in 2000.
Dr. Januzzi is a clinician, teacher and clinical trialist. His research has contributed extensively to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from heart failure and acute coronary syndromes. In addition, he has participated in steering committees, endpoint committees or DSMBs for numerous clinical trials of heart failure therapies, anticoagulants, and diabetes care drugs. He is the principal investigator of the upcoming PROVE HF Study of sacubitril/valsartan, which will examine effects of neprilysin inhibition on ventricular remodeling, symptoms, and biomarker concentrations. Dr Januzzi has published more than 500 manuscripts, book chapters and review articles, has edited two text books on cardiac biomarker testing and the MGH Cardiology Board Review Textbook. He is among the top 1% most cited researchers, according to Clarivate/Web of Science. He is an Associate Editor at both Journal of the American College of Cardiology and Journal of the American College of Cardiology: Heart Failure. He is a member of the ACC Board of Trustees.
